Perspective Therapeutics to Participate at Upcoming April Investor Conferences
April 08, 2024 08:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
March 28, 2024 07:30 ET
|
Perspective Therapeutics, Inc.
SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers...
Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
March 18, 2024 08:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE , March 18, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers...
Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024
March 11, 2024 08:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, March 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility
March 05, 2024 08:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, March 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics Announces $87.4 Million Private Placement
March 04, 2024 09:45 ET
|
Perspective Therapeutics, Inc.
SEATTLE, March 04, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics to Participate at Upcoming Investor Conferences
February 26, 2024 08:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 12, 2024 08:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform
February 01, 2024 08:00 ET
|
Perspective Therapeutics, Inc.
Signs a World-Wide Exclusive License with Stony Brook University for a Novel Platform that can Enhance Radionuclide TargetingReceives up to $2.4M NIH Grant to Develop Differentiated Antibody-based...
Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement
January 22, 2024 16:05 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...